High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?

@article{Amin2013HighdoseII,
  title={High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?},
  author={Asim Amin and Richard L White},
  journal={Oncology},
  year={2013},
  volume={27 7},
  pages={680-91}
}
Immunotherapy with interleukin-2 (IL-2) has been the mainstay of systemic therapy for advanced kidney cancer and melanoma. Although IL-2 treatment is limited to healthy patients, a select group of these patients have derived substantial, durable benefit from it-in some translating into cures with no ongoing therapy or chronic toxicity. Over the past 10 years, insights into the biology of renal cell carcinoma and into key signaling mechanisms in melanoma, and growth in our understanding of… CONTINUE READING